Live Quote · OTCNWPHFHealthcare · Biotechnology

Newron Pharmaceuticals S.p.A.

$20.00▲ 0.00%(+$0.00)

MKT CAP $416.12MNEXT EARNINGS Sep 22, 2026

50%

Bullish

50%

Bullish

TickerSpark Score

42/100

▌ Weak

53

Valuation

60

Profitability

10

Growth

28

Health

60

Momentum

Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NWPHF research report →

Price Chart

+221.54% · this period

52-Week Range100% of range

Low

$9.36

Current

$20.00

High

$20.00

Earnings Calls · NWPHF

Earnings call summaries

Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.

Newron said 2025 was a milestone year for evenamide, with Phase III enrollment progressing, new funding secured, and management highlighting a potential approval path and broader value-creation options in 2026-27.· March 24, 2026

Key Takeaways

Three pivotal evenamide studies are now running globally, with more than 1,300 patients in total.
Management said the new financing and EIB repayment deferral leave the company funded through key readouts.
Ravi Anand highlighted peer-reviewed data suggesting evenamide may improve positive symptoms, negative symptoms, and cognition.
The company expects primary 12-week readouts from ENIGMA-TRS 1 and ENIGMA-TRS 2 within 2026 / early 2027, with NDA preparation underway.
Management is also exploring additional indications, U.S. uplisting/NASDAQ, and possible regional partnering, but said timing depends on data and value.
results":"Newron did not provide a full revenue or EPS breakdown on the call. Roberto Galli said license income decreased versus 2024 because last year included the EA Pharma upfront payment, while 2025 license income included about EUR 8.6 million, with roughly 30% related to Myung In and the remaining part to additional milestone payments from EA Pharma. He also said other income included EUR 1.9 million of R&D tax credit benefit, and that accumulated R&D tax credit benefit since 2025 totaled EUR 25 million, of which EUR 22 million has been used. On cash/funding, Stefan Weber said the company secured access to up to EUR 38 million in February, with EUR 15 million already in the bank, EUR 11 million due before year-end without milestones, and EUR 12 million contingent on positive pivotal results. He also said the EIB agreement delays future payments until at least June 2028. For guidance, management said ENIGMA-TRS 1 is expected to read out by year-end 2026, ENIGMA-TRS 2 may read out around December or early January, and both studies should support regulatory filing; Roberto said the contingent EUR 12 million could extend cash availability to likely the end of 2027.","ceo":"Stefan Weber’s message was strongly optimistic and strategic. He framed the last 15 months as unusually productive, citing the EA Pharma deal, the launch of three pivotal trials, peer-reviewed validation of evenamide’s mechanism, and improved corporate visibility. He also emphasized a longer-term plan to maximize shareholder value through NDA preparation, possible additional indications, and potentially a U.S. listing, while noting that an uplisting is not ready today and would require the right share price and supporting steps.","cfo":"Roberto Galli focused on funding, accounting items, and balance-sheet support for the clinical program. He said Newron ended 2025 with around 20 million shares outstanding, rising to 20.8 million after the capital increase, and about 1.6 million warrants/call options outstanding. He pointed to EUR 8.6 million of license income, EUR 1.9 million of R&D tax credit benefit, and a EUR 2.5 million increase in warrant fair value under IFRS with no cash impact. He also confirmed the EIB repayment delay to June 2028 is included in cash guidance, and said the contingent EUR 12 million from the new financing was intentionally excluded from base guidance because it depends on data.","qanda":"Analysts focused on expansion beyond schizophrenia, cash runway, ENIGMA-TRS timing, and possible partnering. Ravi Anand said he expects evenamide could be useful in bipolar disorder, treatment-resistant depression with psychotic features, and behavioral symptoms of dementia, and reiterated that the effect with clozapine and olanzapine has been particularly notable. On enrollment, he said about 75% of targeted sites have initiated and approximately 300 patients have enrolled in TRS 1, with TRS 2 behind because it only recently started. Management also said TRS 1 and TRS 2 readouts would be announced separately, with TRS 2 likely near year-end or early January, and that further regional deals are possible only if they reflect fair value and the newly granted patent life.","bull":"The call presented evenamide as a de-risked late-stage asset with multiple shots on goal: three pivotal studies active, peer-reviewed clinical and preclinical support, and management expecting readouts within the next 12-15 months. The company also said it has enough funding to reach key milestones, plus potential upside from the contingent EUR 12 million and from possible additional indications or a U.S. listing.","bear":"The main risks are execution and timing: enrollment is still ongoing, TRS 2 is behind TRS 1, and the company is still waiting on definitive pivotal data before filing. Management also acknowledged that U.S. uplisting is not yet ready and that expansion into new indications or regional deals remains preliminary and dependent on future results and valuation."}】}」```python print('done') ```

AI summary of the company's earnings call · Paraphrased · Not investment advice

Newron Pharmaceuticals S.p.A.

Price Chart

About the company

Get TickerSpark's AI analysis on NWPHF

Similar companies

Earnings call summaries

Our NWPHF coverage

No research on NWPHF yet